Compare RCON & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RCON | SCLX |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 27.9M |
| IPO Year | 2008 | 2020 |
| Metric | RCON | SCLX |
|---|---|---|
| Price | $0.90 | $2.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 113.0K | 41.0K |
| Earning Date | 09-30-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,430,788.00 | ★ $30,253,000.00 |
| Revenue This Year | N/A | $118.16 |
| Revenue Next Year | $10.08 | $186.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.02 | $2.45 |
| 52 Week High | $6.42 | $27.00 |
| Indicator | RCON | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.53 | 16.71 |
| Support Level | $0.79 | N/A |
| Resistance Level | $1.04 | $7.77 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 13.29 | 5.06 |
Recon Technology Ltd provides automation systems, industrial equipment, and support services tailored for the oil and gas industry in China. The company's business spans key segments such as automation products and software, equipment and accessories, oilfield environmental protection, and platform outsourcing services. It generates the majority of its revenue by providing integrated automation services to Chinese petroleum companies at oilfields. Its key products and services include pumping unit controllers, natural gas flow computer systems, wireless dynamometers and wireless pressure gauges, and an oilfield monitor and data acquisition system. The company's operations are centered on servicing upstream clients throughout China, with some broader industrial automation solutions.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.